[1]Patel SG, Cohen A, Weiner AB, et al. Intravesical therapy for bladder cancer[J]. Exp Opin Pharmacot, 2015, 16(6): 889-901.
[2]Zirakzadeh AA, Kinn J, Krantz D, et al. Doxorubicin enhances the capacity of B cells to activate T cells in urothelial urinary bladder cancer[J]. Clin Immunol, 2017, 176: 63-70.
[3]Matsumura N, Nakamura Y, Kohjimoto Y, et al. Overexpression of ribonucleotide reductase subunit M1 protein predicts shorter survival in metastatic bladder cancer patients treated with DOXcitabinecontaining combination chemotherapy[J]. Int J Urol, 2017, 24(3): 230.
[4]Ichimi T, Enokida H, Okuno Y, et al. Identification of novel microRNA targets based on microRNA signatures in bladder cancer.[J]. Int J Cancer, 2009, 8(4): 345-352.
[5]Armstrong DA,Green BB,Seigne JD,et al.MicroRNA molecular profiling from matched tumor and bio-fluids in bladder cancer[J].Mol Cancer,2015,14(1):194.
[6]刘禄成, 朱德淳, 温都苏. 膀胱癌相关miRNA的研究进展[J]. 国际泌尿系统杂志, 2010, 30(6): 787-791.
[7]Yang W, Yan HX, Chen L, et al. Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells[J]. Cancer Res, 2008, 68: 4287-4295.
[8]Su HY, Lai HC, Lin YW, et al. Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway[J]. Int J Cancer, 2010, 127: 555-567.
[9]Flahaut M, Meier R, Coulon A, et al. The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/beta-catenin pathway [J]. Oncogene, 2009, 28: 2245-2256.
[10]Noda T, Nagano H, Takemasa I, et al. Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma[J]. Br J Cancer, 2009, 100: 1647-1658.
[11]武健, 吴莺, 孟凡鲁, 等. miR-200c通过 wnt/beta-catenin信号途径抑制SW480结肠癌细胞的侵袭和转移[J]. 江苏医药, 2014, 40(11): 1260-1262.
[12]Du Y, Wang Y, Zhang F, et al. Regulation of metastasis of bladder cancer cells through the WNT signaling pathway[J]. Tumor Biol, 2015, 36(11): 8839.
[13]Ceppi P, Mudduluru G, Kumarswamy R, et al. Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer [J]. Mol Cancer Res Mcr, 2010, 8(9): 1207-1216.
[14]Cochrane DR, Howe EN, Spoelstra NS, et al. Loss of miR-200c: a marker of aggressiveness and chemoresistance in female reproductive cancers [J]. J Oncol, 2010(2010): 821717.
[15]Hamano R, Miyata H, Yamasaki M, et al. Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway [J]. Clin Cancer Res, 2011, 17(9): 3029-3038. |